① Amoy Diagnostics: The company's independently developed FGFR2 gene breakpoint detection kit (fluorescence in situ hybridization) has recently been approved for marketing by the Japanese Ministry of Health, Labour and Welfare. This product is expected to be used for detecting FGFR2 gene fusion or rearrangement in tumor tissues (to help determine whether biliary tract cancer patients are suitable for taking Tasurgratinib). The approval of this product further enriches the company's tumor companion diagnostic product line. ② Jinwo shares: The company plans to implement a restrictive stock-based incentive plan, intending to grant a total of no more than 3.3 million shares of equity to incentive targets, accounting for 4.3% of the company's current total share capital of 76.8019 million shares. The source of the stocks is the stocks issued by the company to incentive targets and the stocks repurchased by the company. ③ Chengdu Dahongli Machinery: Since the establishment of Chengdu Dahongli Building Materials Co., Ltd. ("the joint venture") until now, no actual business has been conducted, and the company has not made actual contributions. In order to optimize the industrial structure, the company has decided to withdraw from the joint venture.